Protein geranylgeranyltransferase type 1 as a target in cancer

Nisar Ullah, Muhammad Mansha, Patrick J. Casey*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

The process of protein prenylation involves the covalent linkage of either farnesyl (15-carbon) or geranylgeranyl (20-carbon) isoprenoid lipds to conserved cysteine residues in the carboxyl-terminus of proteins. Protein geranylgeranyltransferase I (GGTase-I) is the enzyme that catalyzes the addition of the geranylgeranyl moiety from geranylgeranyl pyrophosphate to the target protein, which contains a Cterminal consensus sequence termed a CaaX motif. Geranylgeranylation is important to the function of a number of proteins, including the majority of Rho GTPases, G protein gamma subunits, and several other regulatory proteins. Studies over the past two decades have revealed that many of these proteins contribute to tumor development and metastasis. Blocking Rho GTPase activity through inhibition of GGTase-I in particular has been advanced as a potential strategy for disease therapy. This review will provide an overview of the CaaX prenyltransferases, the rationale for targeting GGTase-I in cancer in particular, and the current status of GGTase-I inhibitor (GGTI) development.

Original languageEnglish
Pages (from-to)563-571
Number of pages9
JournalCurrent Cancer Drug Targets
Volume16
Issue number7
DOIs
StatePublished - 1 Sep 2016

Bibliographical note

Publisher Copyright:
© 2016 Bentham Science Publishers.

Keywords

  • CaaX protein
  • FTI
  • Farnesyl
  • GGTI
  • Geranylgeranyl
  • Isoprenoid
  • Isoprenylation
  • Prenylation

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Fingerprint

Dive into the research topics of 'Protein geranylgeranyltransferase type 1 as a target in cancer'. Together they form a unique fingerprint.

Cite this